IHS Chemical Week

EnviroTech :: Biotech

Crucell and DSM Hit Pharmaceutical Technology Milestone

10:24 AM MDT | June 16, 2008 | Alex Scott

Percivia, a biotech research business jointly owned by biotech firm Crucell (Leiden, the Netherlands) and DSM, says it has significantly raised the yield of its mammalian cell-based technology for producing therapeutic proteins. From the latest test results Percivia says its PER.C6 human cell line, in conjunction with XD Technology generated a record yield of more than 27 grams/liter of therapeutic proteins. The increase compares with a yield in March of this year of just 15 grams/liter. This milstone was achieved using standard bioreactor equipment and readily...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa